Press Releases and News

RedShiftBio Expands Team to Support Demand for AQS3TMpro Read more>

Peer-reviewed study demonstrates higher sensitivity, repeatability, and utility relative to conventional FTIR Read more>

RedShiftBio’s AQS3™pro Goes Global With Appointment of Spinco Biotech as Exclusive Indian Distributor Read more>

RedShiftBio Appoints Primetech as Exclusive Distributor in Japan Read more>

RedShiftBio Appoints Topbiox as Exclusive Distributor in China Read more>

Pressure BioSciences and RedShiftBio Demonstrate Potential of Combining Proprietary Technologies to Enable New Tool for Development and Production of Biotherapeutics Read more>

RedShiftBio Appoints Julien Bradley as new CEO Read more>

RedShiftBio Expands Commercial Team to Support Demand for AQS3pro Read more>

RedShiftBio’s AQS3pro Changes the Game in the Detection and Treatment of Alzheimer’s Read more>

RedShiftBio Shipping AQS3pro as Industry Endorsements Expand Read More>

Photonics Media publishes article on Technological Synergies Move Spectroscopy Out of the Lab Read more>

RedShiftBio’s  AQS3™pro: Finalist in The Prism Awards 2019 Read more>

RedShiftBio’s AQS3pro Wins a ‘The Analytical Scientist Innovation Award’ (TASIA) 2018 Read more>

RedShiftBio to showcase successful studies with biopharma industry leaders at AAPS PharmSci 360 Read more>

Biopharm International interviews scientists with experience of Microfluidic Modulation Spectroscopy for a round-table on how complex protein studies demand dynamic techniques. Visit page 18 to see what Immunogen, Janssen, Elion Labs and the University of Delaware have to say. Read more>

American Pharmaceutical Review publishes article on MMS by Karan K. Shah Principal Development Associate Analytical and Pharmaceutical Sciences ImmunoGen, Inc. Read more>

RedShiftBio Strengthens Focus on Applications with New Hire Read more>

Spectroscopy North America publishes peer-reviewed paper on MMS from Brent Kendrick of Elion Labs, Eugene Ma and Libo Wang of RedShiftBio Read more>

RedShiftBio Expands Team to Support Launch of FlagShip AQS3™pro System for Protein Characterization Read more>

Instrument Business Outlook interviews RedShiftBio CCO Jeff Zonderman on the launch of the AQS3pro Read more>

Spectroscopy Europe highlights the launch of the AQS3pro Read more>

RedShiftBio Launches AQS3pro Protein Characterization System Read more>

RedShiftBio Announces Collaboration Trial Completion Read more>

Jeffrey Zonderman Joins RedShiftBio as its Chief Commercial Officer Read more >

RedShiftBio Inc. Completes $11.0 million Series C Financing Read more >


RedShiftBio® is an innovative provider of analytical instrumentation for the research, development and manufacturing of protein therapeutic drugs.

Read More


The Innovation Awards 2018, the Analytical Scientist
Prism Awards

Contact Us

RedShift BioAnalytics Inc.

131 Middlesex Turnpike
Burlington, MA 01803

T: 781.345.7300
F: 781-345-7301

RedShift™, RedShiftBio®,  See Change®, and AQS3™ are trademarks of RedShift BioAnalytics, Inc.